Related Experiment Videos
Cardiovascular outcomes of treating high blood pressure
1Section of Clinical Pharmacology and Hypertension, Veterans Administration Medical Center, Long Beach, CA 90822.
Insights
Lowering blood pressure helps prevent strokes and heart failure, but coronary events remain a concern. Careful drug selection may improve outcomes and reduce cardiovascular risks.
Area of Science:
- Cardiology
- Hypertension Research
- Clinical Trials
Background:
- Hypertension is a primary risk factor for cardiovascular disease.
- Blood pressure reduction is expected to prevent complications like stroke, heart failure, and renal insufficiency.
- Previous trials show limited reduction in coronary events despite active hypertension treatment.
Purpose of the Study:
- To examine reasons for the disappointing outcome of coronary event reduction in hypertension treatment trials.
- To investigate potential factors contributing to suboptimal blood pressure control and adverse effects in patients on active therapy.
- To explore how careful drug selection can improve blood pressure control and potentially reduce coronary events.
Main Methods:
- Analysis of data from large-scale hypertension treatment trials.
- Review of patient outcomes in active medication groups versus placebo groups.
- Examination of factors such as blood pressure control levels and drug-related adverse effects.
Main Results:
- Patients receiving placebo in trials experienced fewer cardiovascular events than predicted.
- Patients on active hypertension therapy in large studies may have suboptimal blood pressure control.
- Inappropriate therapy may expose patients to adverse effects, impacting outcomes.
Conclusions:
- Despite proven benefits for stroke and heart failure, hypertension treatment has shown limited impact on coronary events.
- Suboptimal blood pressure control and adverse effects of certain therapies may explain this outcome.
- Careful selection of modern antihypertensive drugs can lead to safe and effective blood pressure management, potentially offering direct protection against coronary events and other cardiovascular complications.
Abstract:
Because hypertension is a major risk factor for cardiovascular disease, it has been anticipated that therapeutic reduction of blood pressure would protect patients from serious complications. In fact, this has been shown for strokes, congestive heart failure, and renal insufficiency. But in large trials of hypertension treatment, patients receiving active medications experienced an incidence of coronary events that averaged only 7% lower than that in placebo-treated patients. This report examines some of the reasons for this disappointing outcome. During therapeutic trials patients receiving placebo tended to have fewer cardiovascular events than predicted. However, patients on active therapy in large-scale studies may have suboptimal blood pressure control. They may also be exposed to the adverse effects of inappropriate therapy. Careful selection of modern drugs should allow blood pressure to be controlled in a safe manner, and possibly contribute directly to protection from coronary events and other cardiovascular complications.